Physician

Alkarim Tajuddin, M.D.

According to 2025 Medicare claims, Alkarim Tajuddin, M.D. (NPI: 1922069160) practices hematology/oncology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is NORTHWEST ONCOLOGY AND HEMATOLOGY SC (NPI: 1225099427; TIN: 363395596) and primary practice location at 60169-5036.

Tajuddin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 522 traditional Medicare patients, billed 134,222 HCPCS/CPT codes, and received $1,995,955 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 646 prescription claims across 159 beneficiaries totaling $2,024,019 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 64 claims. Open Payments data shows 69 records totaling $3,668. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,177,169 and ending at $1,995,955. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $538,572 to $2,024,019. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $8,237 and ending at $7,709.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	624	109,720	$1,177,169
2016	688	137,183	$1,503,635
2017	658	122,710	$1,797,713
2018	689	118,716	$1,871,583
2019	696	138,157	$2,149,670
2020	653	137,874	$2,730,650
2021	623	103,293	$1,685,737
2022	628	143,071	$2,069,274
2023	624	185,303	$1,913,589
2024	522	134,222	$1,995,955

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	124	717	$538,572
2016	127	678	$625,822
2017	152	863	$1,078,012
2018	156	1,014	$2,032,654
2019	164	932	$1,258,093
2020	155	863	$1,235,891
2021	178	826	$1,626,163
2022	173	997	$2,040,784
2023	163	827	$1,375,832
2024	159	646	$2,024,019

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	142	$41,269
2016	N/R	92	$4,967
2017	N/R	49	$5,005
2018	N/R	104	$11,232
2019	N/R	119	$12,067
2020	N/R	128	$39,802
2021	N/R	253	$118,391
2022	N/R	57	$6,721
2023	N/R	64	$11,956
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	127	430	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	356	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	128	177	$58
80053	Blood test, comprehensive group of blood chemicals	199	605	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	317	1,167	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	19	570	$265,237
Pomalyst	Pomalidomide	11	308	$236,177
Xarelto	Rivaroxaban	40	1,962	$36,321
Eliquis	Apixaban	42	1,800	$35,669
Imatinib Mesylate	Imatinib Mesylate	22	840	$3,721

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	69	$3,668	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alkarim Tajuddin, M.D.?

Tedicare shows public-source Medicare data for Alkarim Tajuddin, M.D. (NPI 1922069160), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alkarim Tajuddin, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alkarim Tajuddin, M.D.?

Alkarim Tajuddin, M.D. is linked to NORTHWEST ONCOLOGY AND HEMATOLOGY SC (billing NPI 1225099427) in the available physician profile data.

Does Alkarim Tajuddin, M.D. have Open Payments data?

Alkarim Tajuddin, M.D. has 69 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.